The U.S. FBI is investigating corporate giants Johnson & Johnson, Siemens, General Electric and Philips for allegedly paying kickbacks as part of a scheme involving medical equipment sales in Brazil, two Brazilian investigators told Reuters.
The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found.
Five U.S. states filed lawsuits accusing Purdue Pharma LP of illegally marketing and selling opioids, including OxyContin.
Opioid use has reached crisis proportions not only in the United States but also in Canada and some European countries, as prescription opioid painkillers have become much more common, the OECD club of wealthy nations said.
A Japanese government panel approved a price of 33.5 million yen ($305,800) for Novartis’ cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment.
EMD Serono and Pfizer announced that the U.S. FDA approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma.
England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.
Pfizer announced plans to buy Therachon, a rare disease biotech company based in Basel, Switzerland.
With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.
Maine could soon prohibit parents from citing religious or personal beliefs to avoid vaccinating their children, making the U.S. state one of a half dozen cracking down during the nations’ largest measles outbreak in 25 years.